The examination about pharmacokinetics of Tazobactam/Piperacillin [2.25g*2times/day] in the patients who have the blood purification therapy

The examination about pharmacokinetics of Tazobactam/Piperacillin [2.25g*2times/day] in the patients who have the blood purification therapy - The examination about pharmacokinetics of Tazobactam/Piperacillin [2.25g*2times/day] in the patients who have the blood purification therapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019162

Enrollment

Registered

2015-09-30

Start date

2014-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients who have blood purification therapy in the intensive care unit and who need to take Tazobactam / Piperacillin [2.25g*2times/day]

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who have continuous hemodiafilltration therapy in ICU and who need to take Tazobactam / Piperacillin

Exclusion criteria

Exclusion criteria: The patients who don't have continuous hemodiafilltration therapy The patients who don't take Tazobactam / Piperacillin

Design outcomes

Primary

Measure	Time frame
We measure drug level in blood of patients and calculate parameters of population. We compare them with clinical datas and examine relevances blood concentration and expression of side effects.	—

Countries

Japan

Contacts

Public ContactHanako Kohama

Hyogo college of medicine I CU

hanakonakata0828@hotmail.com+81-798-45-6389

Outcome results